...
首页> 外文期刊>Journal of thrombosis and haemostasis: JTH >Recombinant activated factor VII efficacy and safety in a model of bleeding and thrombosis in hypothermic rabbits: a blind study.
【24h】

Recombinant activated factor VII efficacy and safety in a model of bleeding and thrombosis in hypothermic rabbits: a blind study.

机译:在低温兔出血和血栓形成模型中重组活化的VII因子的功效和安全性:一项盲研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Recombinant activated factor VII (rFVIIa) is increasingly used to secure hemostasis in hemorrhagic situations in trauma and surgical patients. Hypothermia is often observed in these clinical settings. OBJECTIVE: To study the efficacy and safety of rFVIIa in hypothermia in a rabbit model of bleeding and thrombosis. METHODS: Sixty-nine rabbits were anesthetized, ventilated and monitored for blood pressure, temperature and carotid flow. The Folts model was used: a stenosis (75%) and an injury were carried out on the carotid artery, inducing thrombosis. Blood flow decreased as thrombus size increased until the pressure gradient was such that the thrombus was released and local arterial blood flow was suddenly restored. This is known as a cyclic flow reduction (CFR). After counting baseline CFRs during a 20-min period (P1), rabbits were randomized blindly to one of four groups: normothermic (NT) placebo or rFVIIa (150 microg kg(-1)), hypothermic (HT) (34 degrees C) placebo or rFVIIa. Then CFRs were recorded over a second period (P2). At the end of the experiment, a hepato-splenic section was performed and the amount of blood loss was recorded. After each period, the following were measured: ear immersion bleeding time (BT), hemoglobin, platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT) and fibrinogen. RESULTS: Hypothermia increased BT and blood loss. These effects were reversed by rFVIIa. In NT rabbits, rFVIIa shortened BT but did not reduce blood loss. rFVIIa-treated rabbits bled similarly regardless of temperature. The incidence of CFRs was higher in treated than placebo animals regardless of temperature. rFVIIa decreased PT and aPTT without modifying platelet count or fibrinogen level. CONCLUSION: Hemostatic efficacy of rFVIIa was maintained in hypothermia. However, the number of CFRs was higher in the rFVIIa-treated group than in the placebo groups, whether for NT or HT rabbits.
机译:背景:重组激活因子VII(rFVIIa)越来越多地用于确保创伤和外科手术患者出血情况下的止血。在这些临床环境中经常会出现体温过低的情况。目的:研究rFVIIa治疗体温过低的兔出血和血栓形成模型的有效性和安全性。方法:对69只兔子进行麻醉,通气并监测血压,体温和颈动脉流量。使用Folts模型:对颈动脉进行狭窄(75%)和损伤,引起血栓形成。血流随着血栓大小的增加而减少,直到压力梯度使得血栓释放并且局部动脉血流突然恢复。这称为循环流量减少(CFR)。在20分钟内(P1)对基线CFR进行计数后,将兔随机分为四组之一:常温(NT)安慰剂或rFVIIa(150 microg kg(-1)),低温(HT)(34摄氏度)安慰剂或rFVIIa。然后在第二个时期(P2)记录CFR。在实验结束时,进行肝脾切片并记录失血量。在每个时期之后,测量以下各项:耳浸式出血时间(BT),血红蛋白,血小板计数,凝血酶原时间(PT),活化的部分凝血活酶时间(aPTT)和纤维蛋白原。结果:体温过低会增加BT和失血量。 rFVIIa逆转了这些作用。在NT兔中,rFVIIa缩短了BT,但并未减少失血。 rFVIIa处理的兔子无论温度如何都类似地出血。无论温度如何,经治疗的CFR发生率均高于安慰剂动物。 rFVIIa降低了PT和aPTT,而没有改变血小板计数或纤维蛋白原水平。结论:rFVIIa在低温下具有止血功效。然而,无论对于NT兔还是HT兔,rFVIIa治疗组的CFR数量均高于安慰剂组。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号